Although Pfizer has dominated the headlines with Comirnaty, it’s not the only company that has created a COVID-19 vaccine using mRNA technology. The biotechnology company Moderna received FDA authorization for its own mRNA COVID-19 vaccine, Spikevax, in December 2021 for administration in individuals 18 years old and older.
President Joe Biden signed orders on Monday to push more government dollars to the U.S. biotechnology industry, as he promoted his initiative to create new treatments and cut the death rate from cancer.
In his role as a medical writer, Willis will develop disease- and treatment-related content to help Peregrine’s pharmaceutical and biotechnology clients communicate the value of their treatments, diagnostics, and medical devices.
Therapeutics isn’t into exercises in futility. The Bay area-based biopharma company is discontinuing enrollment in two arms of its three-arm Phase II study of praluzatamab ravtansine in patients with triple-negative breast cancer (TNBC) after those studies failed to meet the protocol-defined futility boundary.
This industry breakthrough introduces a critical component for the potential treatment of T1D in the setting of an autologous cell transplantation. Type 1 diabetes affects approximately 1.6 million people in the US and more than 20 million people worldwide.
Gradalis, a late-stage stage biotechnology company developing immunotherapies for multiple cancer indications, has named Steven Engle as Chief Executive Officer. Engle joins Gradalis with over two decades of executive leadership experience with public biotech companies developing breakthrough products in the metabolic, autoimmune, oncologic and infectious disease areas. He succeeds founder David Shanahan, who will continue as Gradalis’ Board Chair.